Drug Profile

FcRH5 targeted NK cell engager/IL-15 superagonist - Moderna

Latest Information Update: 27 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Moderna Therapeutics
Class Antineoplastics; Immunotherapies; Recombinant fusion proteins; RNA
Mechanism of Action Immunologic cytotoxicity; Interleukin 15 receptor agonists; Natural killer cell stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Multiple myeloma

Most Recent Events

07 Dec 2024 Preclinical trials in Multiple myeloma in USA (Parenteral), prior to December 2024
07 Dec 2024 Pharmacodynamics and adverse events data from a preclinical study in Multiple myeloma presented at the 66^th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com